Department of Thoracic/Head and Neck Medical Oncology, UT MD Anderson Cancer Center, Houston, TX 77030, USA.
Stat Med. 2012 Sep 28;31(22):2400-13. doi: 10.1002/sim.4485. Epub 2012 May 17.
The future of personalized medicine depends on the ability to efficiently and rapidly elucidate a reliable set of disease-specific molecular biomarkers. High-throughput molecular biomarker analysis methods have been developed to identify disease risk, diagnostic, prognostic, and therapeutic targets in human clinical samples. Currently, high throughput screening allows us to analyze thousands of markers from one sample or one marker from thousands of samples and will eventually allow us to analyze thousands of markers from thousands of samples. Unfortunately, the inherent nature of current high throughput methodologies, clinical specimens, and cost of analysis is often prohibitive for extensive high throughput biomarker analysis. This review summarizes the current state of high throughput biomarker screening of clinical specimens applicable to genetic epidemiology and longitudinal population-based studies with a focus on considerations related to biospecimens, laboratory techniques, and sample pooling.
个性化医学的未来取决于能否高效快速地阐明一组可靠的疾病特异性分子生物标志物。已经开发了高通量分子生物标志物分析方法,以鉴定人类临床样本中的疾病风险、诊断、预后和治疗靶点。目前,高通量筛选允许我们从一个样本中分析数千个标记物,或从数千个样本中分析一个标记物,最终将允许我们从数千个样本中分析数千个标记物。不幸的是,当前高通量方法、临床标本和分析成本的固有性质通常会限制广泛的高通量生物标志物分析。这篇综述总结了目前适用于遗传流行病学和基于人群的纵向研究的临床标本高通量生物标志物筛选的现状,重点介绍了与生物标本、实验室技术和样本混合相关的考虑因素。